- Conditions
- Schizophrenia
- Interventions
- Emraclidine 15 mg, Emraclidine 30 mg, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 19
- States / cities
- Bentonville, Arkansas • Bellflower, California • La Habra, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1825–1848
of 7,062
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Kidney Disease and Hypertension
- Interventions
- Baxdrostat/dapagliflozin, Dapagliflozin in combination with placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 114
- States / cities
- Fairhope, Alabama • Phoenix, Arizona • Surprise, Arizona + 97 more
- Conditions
- Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
- Interventions
- Inebilizumab, Placebo
- Drug · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression
- Interventions
- Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS:, Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS:, Transcranial Magnetic Stimulation (TMS) -- Sham maintenance rTMS
- Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- San Diego, California • New York, New York
- Conditions
- Obstetric Labour, Premature
- Interventions
- Retosiban IV infusion, Placebo IV infusion
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years to 45 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 29 more
- Conditions
- Alcohol Use Disorder
- Interventions
- Zonisamide, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Salmonella
- Interventions
- CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine, Placebo
- Biological · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Refractory Angina
- Interventions
- IMB-1018972, Placebo oral tablet
- Drug
- Lead sponsor
- Imbria Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Migraine Disorders
- Interventions
- sumatriptan succinate/naproxen sodium, placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 34
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • Fair Oaks, California + 31 more
- Conditions
- Crohn's Disease
- Interventions
- Filgotinib, Placebo
- Drug · Other
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 101
- States / cities
- Dothan, Alabama • Sun City, Arizona • Coronado, California + 82 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Ambrisentan, Placebo, Sildenafil, Tadalafil
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
- Conditions
- Atrial Fibrillation
- Interventions
- Melatonin, Placebo (for Melatonin)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Purpura, Thrombocytopaenic, Idiopathic
- Interventions
- eltrombopag, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 26
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 20 more
- Conditions
- Asthma
- Interventions
- SAR231893, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- Bakersfield, California • Culver City, California • Los Angeles, California + 9 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-581, Placebo, D-IVA, TEZ, ELX/TEZ/IVA, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Hyperphagia in Prader-Willi Syndrome
- Interventions
- Carbetocin, Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Orange, California + 16 more
- Conditions
- Common Warts (Verruca Vulgaris)
- Interventions
- Candin, Intradermal Solution, Placebo
- Drug
- Lead sponsor
- Nielsen BioSciences, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Bryant, Arkansas • Fort Smith, Arkansas + 15 more
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
- Interventions
- Eculizumab, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more
- Conditions
- Alcohol Use Disorder
- Interventions
- Placebo, Spironolactone
- Other · Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Depressive Disorder, Major
- Interventions
- Rapastinel, Placebo
- Drug
- Lead sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 40
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Imperial, California + 34 more
- Conditions
- Low Back Pain
- Interventions
- Buprenorphine transdermal system, Placebo
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 539 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 86
- States / cities
- Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 71 more
- Conditions
- Obesity, Non-Alcoholic SteatoHepatitis (NASH)
- Interventions
- Survodutide, Placebo
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 33
- States / cities
- Fountain Valley, California • Gardena, California • Long Beach, California + 29 more
- Conditions
- Sleep Disorders, Circadian Rhythm
- Interventions
- Ramelteon, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 39 more
- Conditions
- Depressive Disorder, Major
- Interventions
- 5 mg BI 1569912, Placebo matching BI 1569912, 10 mg BI 1569912, 20 mg of BI 1569912
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 35
- States / cities
- Bellflower, California • Long Beach, California • Oceanside, California + 31 more